Every material Form 8-K Spectral AI, Inc. has filed with the SEC since July 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Spectral AI posted an investor presentation on its website on September 14, 2026, furnished as Exhibit 99.1 to a Form 8-K. The deck highlights FDA De Novo classification granted May 21, 2026, and a $150 million BARDA contract, but its financial slide shows revenue falling from $29.6 million in 2024 to $19.7 million in 2025 and $7.5 million in the first half of 2026, with a stockholders' deficit of $12.1 million at June 30, 2026.
Presentation posted to the company website September 14, 2026; furnished as Exhibit 99.1.
Revenue: $29.6 million (FY2024), $19.7 million (FY2025), $7.5 million (H1 2026).
Operating loss: $(6.6) million (FY2024), $(8.6) million (FY2025), $(6.3) million (H1 2026).
At June 30, 2026: cash $14.0 million, notes payable $14.9 million, stockholders' deficit $(12.1) million.
Spectral AI reported second-quarter 2026 results on August 11, 2026. Revenue fell to $3.5 million from $5.1 million, gross margin dropped to 31.6% from 45.2%, and the operating loss widened to $4.3 million from $2.1 million. The net loss narrowed to $4.2 million because of a $0.7 million warrant liability gain, and the company reiterated its 2026 revenue guidance of about $18.5 million.
Q2 2026 revenue was $3.5 million versus $5.1 million a year earlier, reflecting lower reimbursed costs under the BARDA contract.
Q2 2026 net loss was $4.2 million, or $0.13 per share, versus $8.0 million, or $0.31 per share, mainly due to a warrant liability fair value change.
Operating expenses rose to $5.4 million from $4.4 million, and gross margin fell to 31.6% from 45.2%.
Cash was $14.0 million at June 30, 2026, and the company reiterated 2026 revenue guidance of about $18.5 million.
Spectral AI appointed Darcy Bajko as Chief Commercial Officer, effective July 31, 2026, to lead commercial functions for the global launch of its FDA-cleared DeepView System for burn indication. The filing sets her base salary at $315,000 and grants options on 150,000 shares, which adds a senior commercial executive and related compensation cost for shareholders.
Darcy Bajko, previously Vice President of Commercialization and Customer Success at MediView XR, starts July 31, 2026.
Base salary of $315,000, with a target bonus of up to 30% of base salary tied to milestones and performance goals.
Stock options for 150,000 common shares under the 2023 Long Term Incentive Plan, vesting annually over three years; options fully vest upon a change of control.
The company's CEO said the first commercial sales of DeepView are targeted by year end 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Spectral AI, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →